European Union

#Cancer drug targets #Cancer research #European Union #Rare disease #Regulatory

EU go-ahead for nasopharyngeal carcinoma drug

The European Commission has approved Tevimbra (tislelizumab), in combination with gemcitabine and cisplatin, for the first-line treatment of adult patients with metastatic or recurrent nasopharyngeal carcinoma (NPC), not amenable to curative surgery or radiotherapy. Nasopharyngeal carcinoma is a rare cancer in which malignant cells form in the nasopharynx, the upper… Read More

#Cancer Research #News #Regulatory

#Drug discovery #Europe #European Commission #European Union

New DDW Highlights podcast: 14 July 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week our news highlights focus on the drug discovery in the European Union, including… Read More

#News

#Drug discovery #Europe #European Commission #European Union

This week in drug discovery (7-11 July) 

News round-up for 7-11 July by DDW Senior Digital Content Editor Diana Turner. This week our news highlights focus on the drug discovery in the European Union, including some new regulatory approvals from the European Commission, advancements from Netherlands-based argenx, a new PhD programme in Estonia, and Switzerland’s… Read More

#News

#Biomedical research #Drug discovery #European Union #Funding #Optibrium #Sustainability

EU-Funded PhD programme to advance sustainable drug discovery

Optibrium has partnered with Tallinn University of Technology (TalTech) to co-supervise an EU-funded PhD position as part of the INNOCHEMBIO programme1. This research project will focus on developing more accurate metabolism models that will reduce the reliance on costly laboratory experiments while improving speed, efficiency and sustainability in drug discovery. Read More

#News

EU flag
#European Commission #European Union #Funding #Research and development

EC urges researchers to “choose Europe for science”

European Commission President Ursula von der Leyen has announced new funding ‘super grants’ at the ‘Choose Europe for Science’ conference.  The substantial additional budget for the development of larger, longer-term grants has been welcomed by the Scientific Council of the European Research Council (ERC).   As… Read More

#News #Trending News

Stamp of approval
#CHMP #EMA #European Medicines Agency #European Union #Marketing approval authorisation

EU’s CHMP supports 14 new medicines, but rejects lecanemab

The European Medicine Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) recommended 14 medicines for approval at its July 2024 meeting. However, the CHMP recommended not granting a marketing authorisation for Leqembi (lecanemab) for the treatment of Alzheimer’s disease. The committee said that the observed effect of Leqembi… Read More

#News #Regulatory #Trending News